Income statement, balance sheet and cash flow statement for the last 8 fiscal years, taken from the XBRL data Grace Therapeutics, Inc. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2020
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
FY2026
Revenue
0.2
100
Cost of revenue
0.08
0
Gross profit
0.12
100
Research and development
29.4
16
4.17
5.56
9.97
4.68
9.51
2.41
Selling and marketing
0.49
2.67
1.14
0.52
0.66
0.25
General and administrative
4.54
5.8
5.52
9.26
7.61
6.68
7.17
8.67
Operating income
-34.4
-24.4
-16.4
-15.6
-52.2
-12.9
-16.7
-11.1
Interest income
0.36
0.34
0.11
0.08
0.25
0.91
0.71
0.69
Other non-operating income
-4.96
-1.08
-3.26
5.12
0.18
-1.83
3.91
1.58
Pre-tax income
-39.4
-25.5
-19.7
-10.5
-52
-14.7
-12.8
-9.49
Income tax
0
0
0
-0.65
-9.54
-1.83
-3.2
-1.7
Net income
-39.4
-25.5
-19.7
-9.82
-42.4
-12.9
-9.57
-7.79
EBITDA
-34
-24
-16.3
-15.6
-52
-12.8
-16.7
-11.1
EPS, basic
-34.33
-14.11
-7.99
-1.62
-5.71
-1.35
-0.79
-0.47
EPS, diluted
-34.33
-14.11
-7.99
-1.62
-5.71
-1.35
-0.79
-0.47
Shares, basic (weighted)
1.15
1.8
2.47
6.13
7.44
9.53
12.1
16.5
Shares, diluted (weighted)
1.15
1.8
2.47
6.13
7.44
9.53
12.1
16.5
Balance sheet
FY2020
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
FY2026
Cash and equivalents
16.9
14.2
50.9
30.3
27.9
23
22.1
17
Short-term investments
8.89
9.79
13.3
0.02
0
Receivables
1.19
0.55
0.53
0.55
0.8
0.72
Other current assets
0.05
0.2
0.34
0.72
0.6
0.28
0.45
0.38
Total current assets
28
18.5
62.4
45.3
29.3
24
22.7
17.4
Property, plant and equipment
2.11
1.91
20.9
0.1
0.02
0.02
0.01
Lease right-of-use assets
0.15
0.09
0.32
0.46
0
Goodwill
13
8.14
8.14
8.14
8.14
Intangible assets
6.39
4.24
0
69.8
41.1
41.1
41.1
41.1
Long-term investments
0.02
Other non-current assets
0.42
0.47
Total assets
36.9
22.9
62.5
129
79.1
73.3
72
66.7
Accounts payable
3.05
1.71
0.12
1.68
1.24
1.01
0.6
0.7
Accrued liabilities
7.7
4.25
0.61
0.3
0.95
0.18
0.66
0.53
Total current liabilities
13.7
7.4
1.58
3.26
3.41
1.68
1.93
2.15
Lease liabilities
0.07
0.19
0.41
0
Total liabilities
25.9
9.86
6.8
20.4
11.2
11.6
5.38
2.76
Paid-in capital
8.15
9.8
10.8
12.2
14
279
293
298
Retained earnings
-101
-126
-146
-156
-198
-211
-221
-228
Other comprehensive income
-7.14
-7.89
-6.33
-6.04
-6.04
-6.04
-6.04
-6.04
Shareholders' equity
11
13
55.7
108
68
61.7
66.6
63.9
Total equity
11
13
55.7
108
68
61.7
66.6
63.9
Total liabilities and equity
36.9
22.9
62.5
129
79.1
73.3
72
66.7
Shares outstanding
7.37
7.44
9.4
13.7
16
Cash flow statement
FY2020
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
FY2026
Net income
-39.4
-25.5
-19.7
-9.82
-42.4
-12.9
-9.57
-7.79
Depreciation and amortization
0.38
0.41
0.14
0
0.12
0.01
0.01
0.01
Stock-based compensation
1.95
1.17
1.34
1.81
0.91
0.73
0.8
Deferred income tax
0
-0.65
-9.54
-1.83
-3.2
-1.7
Change in receivables
-0.62
0.58
-0.06
0.02
-0.3
0.08
0.6
0.11
Change in payables
7.44
-3.39
6.7
2.39
-0.41
Cash from operations
-23
-14.3
-17.2
-15.9
-12.3
-14.9
-8.87
Purchases of investments
-1.92
-9.81
-34.9
-5.02
-6.55
-0.02
0
Cash from investing
8.14
-9.86
-3.52
13.2
0.1
0
0
Stock issued
6.98
59.3
0
0.3
0
0
Cash from financing
13.2
59.5
0
0.3
7.36
14
3.71
Net change in cash
-2.63
36.7
-20.6
-2.46
-4.87
-0.87
-5.16
Income taxes paid
0.01
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $2.12 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Return on equity (ROE)
-41.9%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-40.4%
Net income / average total assets.
Return on invested capital (ROIC)
-54.8%
Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.
Growth
Metric
Value
How it is calculated
Book value growth, 1y
-4.1%
Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y
-2.0%
Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Book value CAGR, 5y
2.8%
Compound annual growth of book value over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y
-7.4%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
-5.6%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
1.3%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y
36.6%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
30.5%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y
46.3%
Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
11.5x
Current assets / current liabilities.
Quick ratio
11.0x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
11.0x
(Cash + short-term investments) / current liabilities.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Operating cash flow per share
-$0.60
Cash from operations / diluted weighted shares.
Book value per share
$2.96
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/B
0.93x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
3.57x
Market cap / tangible book value, when positive.
Earnings yield
-45.3%
Net income / market cap (the inverse of P/E).
Was Grace Therapeutics, Inc. profitable in fiscal 2026?
No. It reported a net loss of $7.8M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.